Superficial spreading melanoma stage III represents a critical phase in skin cancer progression where malignant cells have moved beyond the original tumor site to nearby lymph nodes or surrounding skin areas. Treatment approaches at this stage combine surgical removal with emerging therapies designed to prevent recurrence and improve long-term survival, offering patients more options than ever before.

Managing Stage III Superficial Spreading Melanoma: A Modern Treatment Roadmap

When superficial spreading melanoma reaches stage III, it means the cancer has advanced from its initial site in the skin’s outer layer to involve nearby lymph nodes or surrounding skin tissue. This progression marks an important turning point in treatment planning, as the disease has spread locally but has not yet reached distant organs. Understanding stage III disease helps doctors select the most appropriate combination of therapies to eliminate cancer cells, reduce the risk of recurrence, and support quality of life during and after treatment.^[1]

Stage III melanoma is divided into four subgroups—IIIA, IIIB, IIIC, and IIID—based on how thick the original tumor was, whether the skin surface appeared broken when examined under a microscope (a feature called ulceration), and how extensively cancer has spread to lymph nodes or nearby skin. These subgroups help predict outcomes and guide treatment intensity. The lymph nodes, small bean-shaped structures that filter body fluids and support immune function, play a central role in staging because melanoma often spreads to these tissues first before reaching distant body parts.^[1][2]

Treatment decisions depend not only on the cancer’s subgroup but also on individual factors such as the tumor’s location on the body, the patient’s overall health and fitness level, and personal preferences regarding therapy options. The primary goal is to remove all detectable cancer while using additional treatments to destroy any remaining cancer cells that cannot be seen or removed surgically. Medical societies and cancer organizations worldwide have developed guidelines that help doctors recommend evidence-based approaches tailored to each person’s unique situation.^[2]

Standard Treatment Approaches for Stage III Disease

Surgery remains the cornerstone of standard treatment for stage III superficial spreading melanoma. The primary operation, called wide local excision, involves removing the original melanoma site along with a margin of healthy skin around it to ensure no cancer cells remain at the edges. The width of this margin depends on how deeply the melanoma had penetrated the skin before spreading. This procedure is usually performed under local or general anesthesia depending on the size and location of the area being removed.^[2]

When melanoma has spread to lymph nodes, doctors typically recommend lymph node dissection, a surgical procedure that removes all lymph nodes in the affected region. For example, if melanoma on the leg has spread to groin lymph nodes, surgeons remove the entire group of nodes in that area. This operation helps eliminate visible cancer and provides important information about how extensively the disease has spread, which influences decisions about additional treatment. Lymph node dissection is more extensive than the sentinel lymph node biopsy used for diagnosis, which only samples one or two nodes to check for cancer spread.^[2]

After surgery, many patients receive additional therapy to reduce the risk of melanoma returning. This approach, called adjuvant therapy, targets cancer cells that may remain in the body but are too small to detect with scans or tests. Two main types of adjuvant therapy are used for stage III melanoma: immunotherapy and targeted therapy. These treatments work differently from traditional chemotherapy, which kills rapidly dividing cells throughout the body and often causes significant side effects.^[11]

Immunotherapy for melanoma uses drugs that help the body’s immune system recognize and destroy cancer cells. The immune system normally patrols the body looking for abnormal cells, but cancer cells often develop ways to hide from immune surveillance. Immunotherapy drugs remove these disguises, allowing immune cells to attack the melanoma. These medications are typically given through intravenous infusion every few weeks for up to a year. Common side effects occur when the activated immune system also attacks normal tissues, causing inflammation in organs like the intestines, liver, lungs, or hormone-producing glands. Most side effects can be managed with medications that calm the immune response, but they sometimes require stopping treatment temporarily.^[11]

Targeted therapy is another adjuvant option for patients whose melanomas carry specific genetic mutations. About half of all melanomas have a mutation in a gene called BRAF, which causes cells to grow uncontrollably. Targeted drugs block the abnormal proteins produced by this mutated gene, stopping cancer cell growth. These medications come as pills taken daily for one year. Side effects differ from immunotherapy and may include fever, fatigue, joint pain, skin rashes, and sensitivity to sunlight. Not everyone is eligible for targeted therapy—only those whose tumors test positive for the BRAF mutation through laboratory analysis of the original melanoma specimen.^[11]

The duration of adjuvant therapy typically extends for one year, though clinical trials continue to explore whether shorter or longer treatment periods might be equally effective or safer. During this time, patients see their doctors regularly to monitor for side effects and check for any signs of cancer recurrence through physical examinations and, when appropriate, imaging scans. Clinical guidelines from organizations like the American Cancer Society and Cancer Research UK recommend adjuvant therapy for most patients with stage III melanoma because studies have shown it significantly reduces the risk of the cancer returning.^[11]

For patients who cannot undergo surgery because the melanoma has spread too extensively in a limb or region, or for those whose cancer returns after initial surgery, treatment may include radiation therapy, different immunotherapy combinations, or enrollment in clinical trials testing new approaches. Radiation uses high-energy beams to kill cancer cells in specific areas and may be recommended when complete surgical removal is not possible or when cancer has spread to multiple lymph nodes, suggesting a higher risk of local recurrence.^[2]

Innovative Therapies in Clinical Trials

Clinical trials for stage III melanoma are testing numerous promising approaches that may become standard treatments in the future. These studies evaluate new drugs, different combinations of existing therapies, and novel treatment strategies aimed at improving outcomes while minimizing side effects. Participation in clinical trials gives patients access to cutting-edge treatments before they become widely available and contributes valuable information that helps doctors better treat melanoma in years to come.

One area of active investigation involves optimizing immunotherapy regimens. Researchers are studying whether combining two different immunotherapy drugs works better than using a single drug, despite potentially causing more side effects. These combination immunotherapy approaches use medications that target different checkpoints or braking mechanisms on immune cells, theoretically releasing more powerful anti-cancer immunity. Phase III clinical trials, which compare new treatments against current standard approaches, have shown that some combinations improve the percentage of patients who remain cancer-free several years after treatment, though they also increase the risk of severe immune-related side effects requiring hospitalization and intensive management.

Scientists are also exploring whether shorter courses of adjuvant therapy might work just as well as the standard one-year treatment. These studies aim to reduce the burden of long-term treatment and minimize cumulative side effects while maintaining effectiveness. Phase II trials, which focus on determining whether a treatment works and identifying the best dosing, are testing six-month and three-month adjuvant therapy courses. Preliminary results from some of these studies suggest that shorter treatment may be feasible for selected patient groups, though more follow-up time is needed to confirm long-term outcomes.

Another innovative approach under investigation involves neoadjuvant therapy, which means giving immunotherapy or targeted therapy before surgery rather than after. The idea is that treating the cancer while the tumor and affected lymph nodes are still in place may help the immune system learn to recognize melanoma better, potentially improving long-term control. Several Phase II trials are testing neoadjuvant therapy for patients with large or bulky stage III disease. Early results show that some tumors shrink significantly or even disappear completely with pre-surgical treatment, and in some cases, surgery can be less extensive than originally planned. Researchers are also collecting tumor samples before and after neoadjuvant therapy to understand which patients benefit most and how the treatment changes the tumor’s characteristics.

Researchers are investigating new types of immunotherapy beyond the checkpoint inhibitor drugs currently in standard use. These include therapies that directly activate immune cells to attack melanoma, drugs that modify the tumor environment to make it more susceptible to immune attack, and vaccines designed to train the immune system to recognize melanoma-specific proteins. Some of these experimental treatments are being tested in Phase I trials, which primarily assess safety and determine appropriate doses, while others have advanced to Phase II or III trials in specific patient populations.

Oncolytic virus therapy represents an entirely different treatment concept being studied in clinical trials. This approach uses genetically modified viruses that selectively infect and kill cancer cells while leaving normal cells unharmed. When the virus destroys melanoma cells, it releases tumor proteins that alert the immune system to the cancer’s presence, potentially triggering a broader anti-melanoma immune response. Some oncolytic virus therapies can be injected directly into accessible melanoma deposits in the skin or lymph nodes, making them particularly relevant for certain stage III cases. Phase II trials are evaluating whether combining oncolytic virus therapy with immunotherapy produces better results than immunotherapy alone.

For patients whose melanomas have the BRAF mutation, clinical trials are testing new generations of targeted therapy drugs designed to overcome resistance mechanisms that can develop with current medications. These next-generation inhibitors may work against melanomas that have stopped responding to standard targeted therapy. Other studies are examining whether adding additional targeted drugs that block related molecular pathways can delay or prevent resistance from developing in the first place. These trials typically enroll patients whose melanoma has progressed despite standard targeted therapy, but some are also studying these combinations as initial adjuvant treatment.

Clinical trials for stage III melanoma are conducted at cancer centers throughout the United States, Europe, and other regions worldwide. Eligibility depends on specific criteria including the melanoma’s stage and characteristics, previous treatments received, overall health status, and in some cases, the presence of specific genetic mutations or biomarkers. Patients interested in clinical trial participation should discuss options with their oncology team, who can help identify appropriate studies and facilitate enrollment. Many major cancer centers maintain clinical trial offices that assist with this process.

Understanding Superficial Spreading Melanoma

Superficial spreading melanoma is the most common melanoma type, accounting for approximately two-thirds of all melanoma diagnoses in countries like Australia, New Zealand, and the United States. This form of melanoma develops from melanocytes, the pigment-producing cells in the skin’s outermost layer called the epidermis. The name “superficial spreading” describes how this melanoma initially grows outward along the skin surface rather than immediately penetrating deeper layers—a pattern called radial growth.^[3]

In its early phases, superficial spreading melanoma may remain confined to the epidermis for months or even years, during which time it appears as a slowly enlarging, irregularly pigmented patch on the skin. During this period, the cancer is technically “in situ,” meaning it has not yet invaded through the basement membrane that separates the epidermis from the deeper dermis layer. However, at some point, many superficial spreading melanomas begin vertical growth, with cancer cells penetrating into the dermis and potentially spreading through lymphatic vessels or blood vessels to lymph nodes or distant sites. When this spread reaches regional lymph nodes, the disease has advanced to stage III.^[3]

Superficial spreading melanoma can develop anywhere on the body but shows some patterns related to sun exposure and gender. In men, it most commonly appears on the trunk—the chest, back, or shoulders—areas that often receive intense, intermittent sun exposure. In women, the legs are the most frequent site. However, this melanoma can arise in any location, including areas with minimal sun exposure. About three-quarters of superficial spreading melanomas develop in previously normal-appearing skin, while approximately one-quarter arise within existing moles.^[3]

The appearance of superficial spreading melanoma when it reaches stage III varies considerably. The original skin lesion may show the classic ABCDE warning signs: Asymmetry (one half doesn’t match the other), irregular Borders, multiple Colors within the lesion, Diameter larger than 6 millimeters (about the size of a pencil eraser), and Evolving or changing appearance over time. Colors can include various shades of brown, black, blue, gray, pink, red, or even areas of normal skin color or white scarring. Some melanomas become raised or develop firm nodules, which indicates more aggressive vertical growth.^[3]

Risk factors for developing superficial spreading melanoma include having fair skin that burns easily rather than tanning, a history of blistering sunburns especially during childhood, having more than five atypical or unusual-looking moles, a strong family history with two or more close relatives affected by melanoma, and previous personal history of melanoma or other skin cancers. People with blue or green eyes, red or blonde hair, and significant sun damage on their skin face increased risk. Artificial ultraviolet exposure from tanning beds also raises melanoma risk, regardless of natural skin tone.^[3]

Genetic factors play an important role in superficial spreading melanoma development. Researchers have identified specific gene mutations that occur frequently in these tumors, with the BRAFV600E mutation present in about half of cases. This mutation causes cells to receive constant growth signals, driving uncontrolled division and tumor formation. Understanding the genetic profile of individual melanomas helps predict behavior, assess prognosis, and most importantly, determine whether targeted therapies will be effective treatment options.^[3]

Most Common Treatment Methods

• Surgery
  • Wide local excision removes the melanoma site with surrounding healthy tissue margins to ensure clear edges without cancer cells
  • Lymph node dissection removes all lymph nodes in the region where melanoma has spread, both eliminating visible cancer and providing staging information
  • Surgery remains the foundation of treatment for stage III disease when the cancer can be completely removed
• Immunotherapy
  • Checkpoint inhibitor drugs remove brakes on immune cells, allowing them to recognize and attack melanoma cells throughout the body
  • Given as intravenous infusions typically every two to three weeks for up to one year after surgery
  • Side effects occur when the activated immune system attacks normal tissues, causing inflammation in various organs
  • Combination immunotherapy approaches using two different drugs are being studied in clinical trials to potentially improve effectiveness
• Targeted Therapy
  • Oral medications that block abnormal proteins produced by BRAF or related gene mutations, stopping cancer cell growth
  • Only effective for patients whose melanomas test positive for specific mutations, particularly BRAF
  • Taken as daily pills for one year following surgery to eliminate remaining microscopic cancer cells
  • Common side effects include fever, fatigue, joint pain, skin rashes, and sun sensitivity
• Radiation Therapy
  • Uses high-energy beams to kill cancer cells in specific areas when complete surgical removal is not possible
  • May be recommended when cancer has spread to multiple lymph nodes, suggesting higher risk of local recurrence
  • Sometimes used as palliative treatment to relieve symptoms when cancer cannot be completely removed